568513-U

Discovery^® HS C18 (5 µm) HPLC Columns

L × I.D. 25 cm × 4 mm, HPLC Column

• Synonyme(s) : Discovery RP18 HPLC Column
• Code UNSPSC : 41115700
• eCl@ss : 32110501
• Nomenclature NACRES : SB.52

Propriétés

• product name: Colonne HPLC Discovery^® HS C18, 5 μm particle size, L × I.D. 25 cm × 4 mm
• Matériaux: stainless steel column
• Niveau de qualité: 100
• Agence: suitable for USP L1
• Gamme de produits: Discovery^®
• Caractéristiques: endcapped
• Fabricant/nom de marque: Discovery^®
• Conditionnement: 1 ea of
• Ampleur du marquage: 20% Carbon loading
• Paramètres: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• Technique(s): HPLC: suitable; LC/MS: suitable
• L × D.I.: 25 cm × 4 mm
• Superficie: 300 m²/g
• Couverture de surface: 3.2 μmol/m²
• Impuretés: <10 ppm metals
• Matrice: silica gel, high purity, spherical particle platform; fully porous particle
• Groupe de la matrice active: C18 (octadecyl) phase
• Taille des particules: 5 μm
• Dimension de pores: 120 Å
• operating pH range: 2-8
• Application(s): food and beverages
• Technique de séparation: reversed phase

Description

Application

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research developed a robust RP-HPLC method for the quantitative analysis of molnupiravir, a COVID-19 therapeutic, utilizing nanoformulations. The study highlights the method′s stability and effectiveness in permeability studies, demonstrating its potential in pharmaceutical analysis (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: The study developed and validated an HPLC-UV method for analyzing terizidone in plasma, essential for pharmacokinetic studies in patients with drug-resistant tuberculosis. The method′s reliability supports its use in clinical and pharmacological research (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: This research focuses on optimizing a liquid chromatography method to quantify doxorubicin in plasma and urine. It is crucial for pharmacokinetic, biomedical, and drug monitoring studies, ensuring accurate and precise therapeutic monitoring (Maliszewska et al., 2018).


• Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: This study introduces a universal HPLC-UV method for determining efavirenz in various biological matrices, including transport studies, rat placenta perfusion, and lysate. It is significant for pharmacokinetic and drug distribution research (Zelena et al., 2017).

Caractéristiques et avantages

• Stables, faible relargage pour applications LC-MS
• Changement d′échelle de l′analytique à la préparative
• Haute stabilité pour assurer une excellente reproductibilité d′injection à injection et de lot à lot
• Hydrophobicité plus élevée pour une meilleure résolution des analytes difficiles

   

Produits recommandés

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Informations légales

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany